DRB18 inhibits growth and proliferation in about 90% of the 60 different cancer cell lines in 9 major cancer types. DRB18 treatment leads to significant changes in glucose-based metabolism in A549 lung cancer cells, including cell death via ER/oxidative stress and necrosis.